Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-06-22. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiathe patientmalignancycellsclerosis
  Phrases that lowered it: administrationreceivedmghas historydays
• Sponsor's past termination rate: 3.6% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past trials: 823 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Keywords listed: 8 (lowers risk) · Design
• Number of arms: 1 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 531 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy NCT01051063 · started 2009 · scored riskier than 51% of active trials completed
• Clinical Study of WT2725 in Patients With Advanced Malignancies NCT01621542 · started 2012 · scored riskier than 32% of active trials completed
• Study of 3D189 in Patients With Hematologic Malignancies NCT05320809 · started 2022 · scored riskier than 55% of active trials completed
• Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia NCT04207190 · started 2020 · scored riskier than 80% of active trials completed
• Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission NCT01842139 · started 2011 · scored riskier than 75% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.